Examination of chromosome 7p22 candidate genes RBaK, PMS2 AND GNA12 in familial hyperaldosteronism type II

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 4, 2008, Pages 380-385

  Jeske, Y W A ^a   So, A ^a   Kelemen, L ^a   Sukor, N ^a   Willys, C ^a   Bulmer, B ^a   Gordon, R D ^a   Duffy, D ^b   Stowasser, M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Familial hyperaldosteronism type II; Genetics; GNA12; Hypertension; PMS2; RBaK

Indexed keywords

TRANSCRIPTION FACTOR;

ADRENAL CORTEX ADENOMA; ADRENAL HYPERPLASIA; ADULT; ALLELE; BINDING SITE; CELL CYCLE REGULATION; CHROMOSOME 7P; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; CYP11B1 GENE; CYP11B2 GENE; FAMILIAL DISEASE; FAMILIAL HYPERALDOSTERONISM TYPE II; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENE SEQUENCE; GENETIC LINKAGE; GENOTYPE; GNA12 GENE; HUMAN; HYBRID; HYPERALDOSTERONISM; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE; PHENOTYPE; PMS2 GENE; PROMOTER REGION; RBAK GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE;

5' UNTRANSLATED REGIONS; ADENOSINE TRIPHOSPHATASES; ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 7; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERALDOSTERONISM; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); REPRESSOR PROTEINS; RNA SPLICE SITES;

EID: 40349111232     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.04882.x     Document Type: Conference Paper

References (34)

1. Conn JW. The evolution of primary aldosteronism: 1954-67. Harvey Lect. 1966 62 : 257 91.
2. Gordon RD, Klemm SA, Tunny TJ, Stowasser M. Primary aldosteronism: Hypertension with a genetic basis. Lancet 1992 340 : 159 61.
3. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin. Exp. Pharmacol. Physiol. 1994 21 : 315 18.
4. Young WF Jr. Primary aldosteronism: A common and curable form of hypertension. Cardiol. Rev. 1999 7 : 207 14.
5. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J. Hum. Hypertens. 2000 14 : 311 15.
6. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J. Clin. Endocrinol. Metab. 2000 85 : 2854 9.
7. Lifton RP, Dluhy RG, Powers M et al. A chimaeric 11 beta-hydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992 355 : 262 5.
8. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem. Biophys. Res. Commun. 1995 207 : 565 71.
9. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin. Exp Pharmacol. Physiol. 1991 18 : 283 6.
10. Stowasser M, Gordon RD. Familial hyperaldosteronism. J. Steroid Biochem. Mol. Biol. 2001 78 : 215 29.
11. Stowasser M, Gordon RD. Primary aldosteronism: From genesis to genetics. [Erratum appears in Trends Endocrinol. Metab. 2003 November; 14 (9): 397]. Trends Endocrinol. Metab. 2003 14 : 310 17.
12. Torpy DJ, Stratakis CA, Gordon RD. Linkage analysis of familial hyperaldosteronism type II - Absence of linkage to the gene encoding the angiotensin II receptor type 1. J. Clin. Endocrinol. Metab. 1998 83 : 1046.
13. Torpy DJ, Gordon RD, Lin JP et al. Familial hyperaldosteronism type II: Description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J. Clin. Endocrinol. Metab. 1998 83 : 3214 18.
14. Lafferty AR, Torpy DJ, Stowasser M et al. A novel genetic locus for low renin hypertension: Familial hyperaldosteronism type II maps to chromosome 7 (7p22 J. Med. Genet. 2000 37 : 831 5.
15. Elphinstone MS, Gordon RD, So A, Jeske YW, Stratakis CA, Stowasser M. Genomic structure of the human gene for protein kinase A regulatory subunit R1-beta (PRKAR1B) on 7p22: No evidence for mutations in familial hyperaldosteronism type II in a large affected kindred. Clin. Endocrinol. 2004 61 : 716 23.
16. So A, Duffy DL, Gordon RD et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J. Hypertens. 2005 23 : 1477 84.
17. Skapek SX, Jansen D, Wei TF et al. Cloning and characterization of a novel Kruppel-associated box family transcriptional repressor that interacts with the retinoblastoma gene product, RB. J. Biol. Chem. 2000 275 : 7212 23.
18. So A, Jeske YW, Gordon RD, Duffy D, Kelemen L, Stowasser M. No evidence for coding region mutations in the retinoblastoma-associated Kruppel-associated box protein gene (RBaK) causing familial hyperaldosteronism type II. Clin. Endocrinol. 2006 65 : 829 31.
19. Chan AM, Fleming TP, McGovern ES, Chedid M, Miki T, Aaronson SA. Expression cDNA cloning of a transforming gene encoding the wild-type G alpha 12 gene product. Mol. Cell. Biol. 1993 13 : 762 8.
20. Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc. Natl Acad. Sci. USA 1999 96 : 10 764 9.
21. Wu J, Gu L, Wang H, Geacintov NE, Li GM. Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis. Mol. Cell. Biol. 1999 19 : 8292 301.
22. Nicolaides NC, Papadopoulos N, Liu B et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994 371 : 75 80.
23. Lynch HT, Guirgis HA, Lynch PM, Lynch JF, Harris RE. Familial cancer syndromes: A survey. Cancer 1977 39 (4 Suppl 1867 81.
24. Gordon RD. Primary aldosteronism and other forms of mineralcorticoid hypertension. In : Swales JD (ed.). Textbook of. Hypertension. Blackwell Scientific, Oxford. 1994 865 92.
25. De Vos M, Hayward BE, Picton S, Sheridan E, Bonthron DT. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am. J. Hum. Genet. 2004 74 : 954 64.
26. Nicolaides NC, Carter KC, Shell BK, Papadopoulos N, Vogelstein B, Kinzler KW. Genomic organization of the human PMS2 gene family. Genomics 1995 30 : 195 206.
27. Chip-Mapper. CHIP MAPPER - Multi-genome Analysis of Positions and Patterns of Elements of Regulation. Access. http://mapper.chip.org/mapper/ mapper-main.
28. Chapman MS, Qu N, Pascoe S et al. Isolation of differentially expressed sequence tags from steroid-responsive cells using mRNA differential display. Mol. Cell. Endocrinol. 1995 108 : 27.
29. Bhalla V, Soundararajan R, Pao AC, Li H, Pearce D. Disinhibitory pathways for control of sodium transport: Regulation of ENac by SGK1 and GILZ. Am. J. Physiol. Renal Physiol. 2006 291 : F714 21.
30. Fearns C, Pan Q, Mathison JC, Chuang TH. Triad3A regulates ubiquitination and proteasomal degradation of RIP1 following disruption of Hsp90 binding. J. Biol. Chem. 2006 281 : 34 592 600.
31. Fraser CC. Exploring the positive and negative consequences of NF-kappaB inhibition for the treatment of human disease. Cell Cycle 2006 5 : 1160 3.
32. Newton-Cheh C, Guo CY, Gona P et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. [see comment]. Hypertension 2007 49 : 846 56.
33. Stowasser M, Gordon RD. The aldosterone-renin ratio in screening for primary aldosteronism. Endocrinologist 2004 14 : 267 76.
34. Gordon RD. Diagnostic investigations in primary aldosteronism. In : Zanchetti A (ed.). Clinical Medicine Series on Hypertension. McGraw-Hill International, London. 2001 101 14.